INTRODUCTION
Biotechnology is a key technology in the generation of an adequate food supply for the ever growing human population. The main objectives of using this biotechnology in dairy cattle are to increase production, reproductive efficiency and rates of genetic improvement. To achieve this goal, reproductive biotechnologies like: -artificial insemination (AI), synchronization, Embryo transfer (ET), in-vitro fertilization (IVF) cloning, and newly emerging biotechnologies like stem cell therapy. It can prevent venereal transmission of sexually transmitted diseases; increases milk production and also reproduce disease resistant offspring (Shibiru et al., 2017) .
Stem cells are the cells that have the ability to differentiate into different mature cells like hepatocytes, myocytes, neurons and others. In early embryos all cells are totipotent stem cells, as they have the ability to form all tissues of the organism. There are also stem cells in adult tissues that contribute to the renewal and regeneration of specific tissues (Ali et al., 2016) . It used to repair system for the body, these cells in most multicellular organisms. It has capability to maintain and multiply meiotically and differentiates into a diverse range of specialized cells types (Munoz et al., 2009 ).
Historically, SC research began in 1981 with the milestone publication report the establishment of murine ESC. Initial use of stem cells into veterinary SCs therapy began in 1995 with injections of unprocessed bone marrow into equine suspensory ligaments. Purifying activities have been reported in the processing of fresh adipose SCs and expansion of SCs (either from bone marrow or adipose) through culture (Julie, 2013) . In the last 20 years, considerable attention has been given to the research about the biology of SCs. Hence, there was a significant increase in the understanding of its characteristics and therapeutic potential for its application in different areas (Lane et al., 2014; CollartDutilleul et al., 2015) .
It offers an unprecedented hope in to become some or all of more than 200 different cell types treating many degenerating diseases of humans and animals (Zwaka and Thomson, 2003) . Almost all animal tissues may be repaired or regenerated by the direct action of SC (Da Silva Meirelles et al., 2006) , which presents a high potential for multiplication and differentiation (Snippert and Clevers, 2011) . Stem cells are undoubtedly, most promising for cell-based therapies that are currently tested in pre-clinical trials for a wide range of ailments for their therapeutic potential (Ribitsch et al., 2010; Spencer et al., 2011) .
The previous studies in Veterinary sciences mostly focused on establishing procedures for isolation and their characterization of stem cell, but with advancement in array of techniques for invitro studies, stem cells rapidly became a viable tool for regenerative therapy. The multi-potential capability of stem cells can be better utilized to overcome the challenges faced by the clinicians .
The applications stem cell as therapeutic potential in veterinary practice is less extensive or not widely used, even though many degenerative disorders are challenging due to their unresponsiveness to available drugs. 
Sources of Stem Cells
Stem cells are categorized into four types based on their sources. These classifications contain SCs from embryos, SCs from fetus, SCs from the umbilical cord and SCs from the adult (Lodi et al., 2011) .
Embryonic stem cells
Embryonic stem cells are obtained from the inner cell mass (ICM) of blastocyst during embryonic development, the ICM develops into two distinct layers; the epiblast and the hypoblast. The hypoblast forms the yolk sac and the epiblast differentiates into three primordial germ layers (ectoderm, mesoderm and endoderm). ESCs present two distinctive properties: they are able to differentiate into all derivatives of three primary germ layers (pluripotency), and they are capable of propagating themselves indefinitely under defined conditions (Odorico, et al., 2001 
Stem cells from umbilical cord
Umbilical cord contains circulating SCs. The cellular contents of umbilical cord blood appear to be quite distinct from those of bone marrows and adult peripheral blood (Rogers and Casper, 2004) . The frequency of umbilical cord blood hematopoietic SCs equals or exceeds that of bone marrow and they are known to produce large amount of blood cell colonies invitro. They have long telomeres and can be expanded in long term culture (Hui et al., 2011) .
Umbilical cord and cord blood-derived SCs remain the world's largest potential source of SC (Kita et al., 2010 
Induced pluripotent stem cells (iPSCs)
Induced pluripotent stem cells (iPSCs) are obtained by in vitro transformation of cultured adult somatic cells with genes encoding transcription factors crucial for the development of embryonic stem cells (Oct-4, Klf4, Nanog, cmyc) . The resultant iPSCs possessed the immortal growth characteristics of self-renewing ESCs. For example induced pluripotent stem cells were injected into mouse blastocyst and they contributed to a variety of diverse cell types, demonstrating their developmental potential (Takahashi and Yamanaka, 2006) .
Figure1. Developmental hierarchy in stem cell compartment (Ratajczak et al., 2008).

Types of Stem Cells
Stem cells have several characteristics that make them unique in comparison with other mammalian cells. SCs definition includes three main criteria (Verfaillie, 2009 ). Ability to selfrenew for several cell divisions, which is a prerequisite for sustaining the SC pool, ability to generate at the single cell level differentiated progeny cells, in general of multiple lineages and ability to functionally reconstitute a given tissue invivo. When unspecialized SC diff erentiates, it assumes characteristics of a specific tissue (Verfaillie, 2002 ).
Based on Potency
Potency refers to which cell types of a given SC can differentiate into types and number of body cells. The higher the potency, the greater number of tissues the cell can form. Based on their potency, SCs can be classified into five different types (Schöler, 2007) . 
Pluripotent stem cells:
These cells can form all cells in the adult, but cannot form placenta. Embryonic stem cells found in a day-5 blastocyst are pluripotent (Schöler, 2007) .
Multipotent stem cells:
The cells that have the potential to make several different cell types of related cells. Examples of multipotent cells include MSCs which have the ability to differentiate into many different tissue types and hematopoietic SCs that can form all the cellular components of blood .
Oligopotent stem cells:
Stem cells that have the ability to form two or more cell lineages in a tissue, e.g. neuronal stem cells with ability to form different neurons types (Bajada et al., 2008) .
Unipotent stem cells:
The prefix "uni-" suggests, this cell type has only the ability to differentiate into one type of cell, typically the tissue from which the SC was derived. An example of this can be epithelial stem cells which appear to only be capable of making epithelial cells (Yao et al., 2012 ). 
Comparative Uses Types of Stem Cell
Table1. Comparison of types of stem cells based on their advantages and disadvantages
They can be obtained from umbilical cord after birth and can able give rise three embryonic germ line in the presence of inducers (Emadedin et al.,2012) The main disadvantage of cord blood is that the volume collected is fixed and relatively small. Therefore, the number of stem cells available for transplantation is low compared to the number of cells that can be collected in customizable bone marrow or peripheral blood stem cell harvests (Lisa et al., 2016)). Adult stem cell Easy to get
Clinical Application of Stem Cells
The general principle of SC therapy is to utilize the natural ability of the animal and human body to heal tissues through the process of regeneration. SCs are ideal candidates for use in regenerative medicine, tissue engineering, gene therapy, cell replacement therapies and cancer therapeutics. It may be possible to use SC therapies to combat major diseases such as heart disease, bone or connective tissue disorders, neural defects and hematological disorders (Korbling and Estrov, 2003).
Bone Regeneration
The mesenchyma stem cells can undergo osteogenic differentiation and exploration of the potential for using autologous SC therapy to increase bone repair and regeneration is well reported (Amarpal, Bone marrow derived SCs were injected at the site of a non-union in a non-healing fracture of the humerus bone in dog. One month later, the animals showed good bony union without the signs of lameness by Ryan et al. (2005) . Ease of availability and capability of allogenic bone marrow derived mesenchymal stem cell (BMMSCs) to avoid immune rejection have made these cells an attractive alternative to autogenic bone marrow-derived cells for reconstructive surgery (Arinzeh et al., 2003) .
Spinal Cord Regeneration
Acute spinal injuries are common in canines and felines that lead to loss of tissue, including myelinated fibre tracts that responsible for carrying nerve impulses. The nervous tissue has limited regeneration capacity and complete restoration of locomotor activity is a challenge to modern therapeutics. The MSCs were found to have the ability to differentiate into oligodendrocytes and other cell types needed to restore neuronal function in injured spinal cord (Dobkin et al., 2006; Harris, 2008 Traumatic spinal cord injury (SCI) can lead to severe neurological damage. Even though endogenous SCs are present, recovery from this injury is difficult. A strategy to increase axonal regeneration could involve transplantation of SCs into the injured spinal cord. Five patients with acute SCI, these were treated by bone marrow derived cells and granulocytemacrophage colony stimulating factor (GM-CSF). GM-CSF is a signaling molecule that induces proliferation and differentiation of bone marrow cells. Also, it possibly leads to proliferation of endogenous neural stem cells, inhibits apoptosis and activates macrophages which remove the myelin debris inhibiting regeneration. The patients showed sensory and motor function improvements with no complications (Park et al., 2005) .
Neural cell SC therapy has raised the hopes in order to treat neurodegenerative diseases; which is not responsive to other treatments. In order to properly integrate in the brain cell that is injured, isolation as well as enrichment and propagation of neural SCs are necessary. Use of compliant conditions of culture and differentiation of both embryonic as well as somatic SCs in a directional manner, the clinical application of such therapies is possible nowadays (Kim and De Vellis, 2009).
Tendon regeneration
Tendon naturally heals (repairs) well, but the scar tissue formed in this repair is functionally deficient in comparison to normal tendon; this has important consequences for the animal in terms of reduced performance and a substantial risk of re-injury (Dowling, 2000) . Due to the lack of effective treatments available for tendon related injuries; researchers have started to investigate the therapeutic potential of MSC for tendon repair. Recently, there has been particular interest in utilizing MSC therapy for tendon repair of race horses. Preliminary studies have described beneficial results following administration of undifferentiated autologous MSC, with functional recovery reported in nearly 90% of the horses with partial tendon damage (Pacini et al., 2007) .
Mesenchymal stem cells are characterized by their unique cell surface marker proteins like: adhesion molecule, cytokines, growth factors and their receptors, extracellular matrix molecules, and their multilineage potential. These are added value to the applications of the MSCs due to their hypoimmunogenicity from lack of the major histocompatibility complex II molecular expression (Uccelli et al., 2006) . In equine, autologous of BM MSCs after invitro expansion were used and found to be effective for regeneration tendon matrix in superficial flexor tendon injury . The collagenase induced tendinitis in the superficial digital flexor tendon in 8 horses was treated with adipose derived nucleated cells. The treated group showed improved tendon organization as exhibited by cartilage oligomeric matrix protein expression (Nixon et al., 2008) .
Ligament regeneration
Most of the time race horses are especially prone to injuries of the ligaments and full functional recovery of the horses via conventional therapies is unsatisfactory. Equine suspensory ligament injuries are challenging because healing process is slow and re injuries are common (Watanabe et al., 2002) . Natural healing when continues for long periods ultimately results in scar tissue formation that reduces the flexibility and movement of joint rendering the horses useless. The mechanical properties of healing ligaments are also not comparable to those of normal tissue. The quality of the ligament healing can be improved with altered therapeutic strategies including SC therapy. Ligament healing can also be enhanced by transplantation of MSCs which are demonstrated to differentiate into fibroblast like cells in ligament injury sites (Carvalho et al., 2011) .
Cartilage Regeneration
Cartilaginous injuries can arise from either traumatic injury or disease. SC therapy, utilizing culture expanded MSC has been suggested as a potential reparative treatment following successful outcomes in small and large animal models (Chang et al., 2008) . Single intraarticular injection of AD-MSC has been found to be efficacious in chronic osteoarthritis of the coxofemoral joint in dogs. Mesenchymal stem cells play an important role in regeneration of injured joint. Similarly, MSCs play a potentially important role in regenerating injured joints (Gade et al., 2012a .
Mesenchymal stem cells can differentiate into chondrogenic lineage (Dennis et al., 2002) and can be used to treat cartilage defects. In rabbits, repair of full thickness defects of articular cartilage was observed; after transplantation of autologous MSCs dispersed in a type I collagen gel . Similarly, in the same animal model, encouraging results were obtained, after injecting calcium phosphate and hyaluronan sponge previously loaded with autologous bone marrow derived MSCs in knees with osteochondral defects (Debari et al., 2003) . In a caprine osteoarthritis model it was found that the local delivery of adult MSCs to injured joints stimulates regeneration of meniscal tissue and retards the progressive destruction (Murphy et al., 2003) .
Canine MSCs seeded in type I collagen glycosaminoglycan matrices were used in dogs for repair of cartilage defects of knee joints (Xiang et al., 2006) . In large animal models, like sheep MSCs used for repair of chronic osteochondral (Dattena et al., 2009; Zscharnack et al., 2010) . MSC therapy provides a simple, arthroscopically applicable and clinically effective approach for cartilage repair. Injecting MSC directly into the joint and is considered as a recent development. Such treatment in dogs has resulted in greater flexibility in joints and less pain (Csaki et al., 2007) .
Wound Healing
Autologous bone marrow derived nucleated stem cells have been transplanted in experimental rabbits and clinical cases to evaluate their tissue regeneration potential in full thickness wounds ), burn wounds (Oloumi et al., 2008) and corneal alkali burn wounds (Ye et al., 2006) . Several studies indicated that MSCs derived from the bone marrow could significantly impact wound healing in diabetic and non-diabetic animals through cell differentiation and the release of paracrine factors. Culture expanded BM-MSCs have been shown to promote the healing of diabetic wounds (Wu et al., 2010) . Adult bone marrow stem cells give rise to epidermal keratinocyte, follicular epithelial cells, sebaceous gland cells and dendritic cell after their transplantation in mice (Krause et al., 2001 ).
Bone marrow derived mesenchymal stem cell were injected around wound and their application to the wound bed in an excisional wound model enhanced healing significantly in normal and diabetic mice as Wu et al.(2007) . BM-MSCtreated wounds exhibited significantly faster wound closure with increased reepithelialization, cellularity and angiogenesis. In addition to differentiating into keratinocytes and forming appendage like structures, BM-MSCs in the wound enhance the proliferation of endogenous keratinocytes and increase the number of regenerating appendage like structures (Wu et al., 2007) .
Cardiac Repairing
The SC therapy would minimize loss of cardiomyocytes by reducing cell death, promote the return of a stunned, hibernating myocardium to normal function, stimulate revascularization of the damaged region by enhancing angiogenesis, regenerate viable cardiomyocytes thereby preserving contractile function and reducing the opportunity for scarring (Caspi et al., 2007) . MSCs when therapeutically used they improve the function of heart after an acute myocardial infarction. This could be due to the fact that MSCs can generate various signalling molecules that are cardio-protective and can differentiate into a myocyte as well as into the lineage of the vascular system (Udehiya et al., 2013).
Treatment of Diabetes Mellitus
Type-I diabetes is caused by the reduction or the absence of the hormone insulin, while Type-II is caused by a lack of response to insulin. Insulin is produced by the β-cells of the pancreas and stimulates the uptake of glucose from the blood into cells. Without insulin the resulting high levels of glucose in the blood can cause multiple medical complications. Diabetes can be temporarily controlled by the administration of exogenous insulin, but the only potential cure is offered by pancreatic transplantation or by cell therapy. Recent advances in SC therapy understanding and technology have suggested the use of pluripotent stem cells as a source of β-cells (Mayhew and Wells, 2010) . In Ethiopia there is no any report of therapeutic use of stem cell in veterinary medicine.
Challenges and Limitation of Stem Cells Therapies
There are many challenges that are necessary to explore and fasten the growth of SC therapies. As example Embryonic stem cells (ESC) have unlimited self-renewal ability and the capacity to differentiate into any specialized cell type, therefore, could represent an unlimited cell source for tissue regeneration. However, research on these cells has been hampered or banned in some countries because of the ethical concerns about destroying human embryos and animal welfare to obtain them (Cet Stem BioPharma website, 2018, American Veterinary Medical Association website, 2018). Another major limiting factor for their usefulness in clinical therapy lies in their risk of uncontrolled growth and potential danger of teratoma formation and immunological intolerance (Solter, 2006) .
The use of SC in cells and tissue transplantation as therapeutic require donor and recipient tissues to be compatible. The major difficulties scientist encounter is the identification SCs from adult tissues and the process to successfully trigger differentiation in to the desired cell type is another challenge for researchers. The cost is extremely expensive (Zhili et al., 2014 ).
CONCLUSION AND FUTURE PROSPECTIVE OF STEM CELL THERAPY
Stem cells are most promising for cell-based therapies, thereby provides a powerful and flexible option for veterinarians to restore function and improve animal health through the novel techniques. The capability of SCs to self replicate to differentiate into a specific, more specialized cell type is what makes useful in the treatment of specific disease. In veterinary sciences, SCs are mainly used for the treatment in canines and equines whereas research is still going on in other farm animals. However, their extensive use in all clinical condition cannot be exploited because of high treatment expenditure, certain chronic and irreparable conditions can be better treated with these cells and the cost of production will hopefully be reduced when extent of production is increased. Although SCs have immense potential in therapeutics, their full clinical uses requires extensive research for standardization of the treatment protocols, routes and doses. Further, guidelines and regulations for the controlled use of SCs in animals will become a near future need.
Based on the conclusion above, the following suggestions and recommendations are forwarded:
 The research should be continued on stem cells area to understand the several characteristics, molecular control and regulation in the SCs.
 The veterinarians, researchers and scientist need be aware of SC based therapies, concerning its regulations and application to ensure therapeutic use to animal.
 Other alternatives source of SC like mesenchyma stem cell should be used in ethical issues associated without destructing embryos and animal welfare affecting.
 Health sector along with government support should focus on research and clinical therapies in reasonable price in area of SCs.
 The knowledge about stem cell should be increased for better use through storing of stem cell and its dose to be used
